Revised Ph. Eur. Monographs on Excipients due to ICH Q3D

Recommendation
18-20 November 2025
Heidelberg, Germany
GMP and FDA Compliance in Pharmaceutical Development and IMP Manufacturing
Several revised Ph. Eur. Monographs on excipients commonly used in semi-solid formulations (e.g. oils, fats, waxes, emulsifiers) have been proposed in Pharmeuropa 30.2. Deadline for comments is June 30, 2018.
In line with the Ph. Eur. implementation strategy for the ICH Q3D guideline on elemental impurities, the test on Nickel is proposed for deletion as the relevant elemental impurities are considered to originate from the production process. A change to this effect has been introduced in the Production section of the general Ph. Eur. monograph “Substances for pharmaceutical use” (with Ph. Eur. supplement 9.3), as only the manufacturer of a substance for pharmaceutical use knows which elemental impurities may be potentially introduced as catalysts and reagents, and whose levels would therefore need to be controlled.
This affects the following Ph. Eur. Monographs:
- Hard fat
- Hard fat with additives
- Arachis oil, hydrogenated
- Castor oil, hydrogenated
- Cottonseed oil, hydrogenated
- Glycerol dibehenate
- Glycerol distearate
- Glycerol monostearate 40-55
- Macrogol 15 hydroxystearate
- Macrogol 30 dipolyhydroxystearate
- Palmitic acid
- Stearic acid
- Soya-bean oil, hydrogenated
- Squalane
- Triglycerides, medium-chain (additional removal of the tests for Chromium, Copper, Lead, Tin)
Furthermore, a draft for a new monograph on Cocoa butter has been published for comment in the same issue of Pharmeuropa.
For more information plese see Pharmeuropa Online.
Related GMP News
09.05.2025New ECA Guidance on Sampling and Sample Management
07.05.2025Public Consultation on ICH M13B Guideline on Bioequivalence launched in Switzerland
07.05.2025BioPhorum publishes Guidance for ICH Q2(R2) and Q14 Implementation
23.04.2025OTC Drug Production Ceased after FDA Warning Letter
23.04.2025EMA publishes Draft of ICH M13B Guideline on Bioequivalence
16.04.2025EMA publishes four new product-specific Bioequivalence Guidance